Prerakkumar Parikh, PharmD, of Megallen Rx Management/Prime Therapeutics, detailed the impact of formulary placement of biosimilars on cost burden along with how stakeholders can work with pharmacy benefit managers to promote biosimilar use.
Prerakkumar Parikh, PharmD, director of specialty clinical solutions at Magellan Rx Management, explains the roles of formulary placement and tiering by pharmacy benefit managers (PBMs) in relation to biosimilars and how they affect the cost-sharing burden for patients who choose them. He also discusses how stakeholders, like health care providers and policymakers, can work with PBMs to promote the use of biosimilars.
Parikh went into more detail on biosimilars during the AMCP Nexus session, "Biosimilar Operational Readiness: Managed Care Stakeholder Response to Market Expansion Impact.
Transcript
Can you explain the roles of formulary placement and tiering by PBMs? How do these decisions affect the cost-sharing burden for patients who choose biosimilars over reference biologics?
The tiering, some of the biosimilars that have came out are in the specialty tier. So far on the pharmacy benefit side, we are seeing the adalimumab biosimilars on that specialty tier along with the brand name product, Humira.
So, what that will do is it will allow for access. At the same time, if you have a low-WAC [wholesale acquisition cost] biosimilar at the same level as Humira, and if a patient is paying a percentage coinsurance on that specialty tier, a low-WAC biosimilar is going to reduce that cost for the patient, as well.
How can stakeholders, including policymakers, manufacturers, and health care providers, work with PBMs to promote biosimilars and encourage adoption?
The biggest factor into promoting biosimilar use and encouraging the use will be to educate patients and educate providers. I think we as an industry, all the stakeholders, need to make sure that we have resources that help the providers and the patients understand the value of biosimilars, the cost savings from biosimilars, and, at the same time, how biosimilars have the same clinical efficacy and safety as the reference product.
ATS 2024: Bridging the Past, Present, and Future of Respiratory Care
May 16th 2024The application of artificial intelligence in medicine is anticipated as a highlight of ATS 2024, with sessions exploring its applications in research, radiological interpretation, and pediatric pulmonology.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More